Tablet formulation

TW202631137APending Publication Date: 2026-08-01ASTRAZENECA IRELAND LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
ASTRAZENECA IRELAND LTD
Filing Date
2025-12-05
Publication Date
2026-08-01

Smart Images

  • Figure TWG2TA001071385_001
    Figure TWG2TA001071385_001
  • Figure TWG2TA001071385_002
    Figure TWG2TA001071385_002
  • Figure TWG2TA001071385_003
    Figure TWG2TA001071385_003
Patent Text Reader

Abstract

This specification relates to a pharmaceutical formulation comprising N-[(8R)-4-(1-methyl-2-sideoxy-1,2,3,4-tetrahydro-6-quinolinyl)-5,6,7,8-tetrahydro-8-isoquinolinyl]propionic acid (baxdrostat), its tablets, and its use in therapy. This specification also relates to a procedure for manufacturing the tablets. The specification relates to a pharmaceutical formulation comprising N-[(8R)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydro-6-quinolinyl)-5,6,7,8-tetrahydro-8-isoquinolinyl]propanamide (baxdrostat), tablets thereof, and their use in therapy. The specification also relates to a process for manufacturing the tablets.
Need to check novelty before this filing date? Find Prior Art